How can innovation, philanthropy, and artificial intelligence help accelerate breakthroughs in breast cancer research?

In this NYSE Live interview during Breast Cancer Awareness Month, Wendy Holmes, Advisory Board Member at the Breast Cancer Research Foundation (BCRF) and Private Wealth Advisor at UBS, discusses BCRF's new $100 million venture fund, advances in breast cancer research, and the growing role of AI in early detection and prevention.

Holmes explains that the newly launched venture fund was designed to help bridge a critical gap between scientific discovery and commercial application. Many promising research projects and medical innovations require additional support to move from the laboratory into real-world healthcare settings, and the fund aims to accelerate that process by providing critical capital and resources.

A major focus of the conversation is the role of innovation in advancing breast cancer care. Holmes highlights Clarity Breast, an AI-powered screening platform developed by Dr. Connie Lehman, which uses mammography and artificial intelligence to help assess breast cancer risk years before a diagnosis may occur. The technology represents an example of how research-backed innovation can improve patient outcomes and expand early detection capabilities.

The interview also examines the importance of collaboration within the scientific community. Holmes shares insights from a recent gathering of researchers supported by BCRF and discusses how collaboration across institutions, disciplines, and geographies can accelerate progress toward new treatments and potential cures.

Another key topic is the scale of BCRF's research efforts. Holmes explains how the organization supports hundreds of researchers worldwide and continues to invest significant resources into advancing breast cancer science. Through grant funding, partnerships, and strategic initiatives, the foundation seeks to support discoveries across prevention, diagnosis, treatment, and survivorship.

The conversation further explores the growing concern surrounding breast cancer incidence among younger women. Holmes discusses why awareness, screening, and research remain critically important and highlights the need for continued investment in understanding risk factors and disease progression.

Artificial intelligence is another major theme. Holmes explains how emerging technologies are creating new opportunities for earlier detection, risk prediction, and personalized approaches to care. She discusses how AI-driven tools may complement traditional screening methods and improve clinical decision-making.

The interview also highlights the intersection of philanthropy and healthcare innovation. Drawing on her experience as both a financial advisor and nonprofit leader, Holmes discusses the importance of strategic giving, responsible stewardship of capital, and empowering donors to support meaningful causes that generate long-term impact.
Throughout the discussion, Holmes provides perspectives on breast cancer research, philanthropy, healthcare innovation, artificial intelligence, early detection, women's health, medical technology, and the future of cancer treatment.

Disclaimer: Informational content only. NYSE does not endorse or recommend investments, strategies, companies, products, or services discussed.